Developer docs
API playgroundTry for free, no card

Search company profiles

Araris Biotech

Full company profile

uuid0000bh3

Namestring
Araris Biotech
Legal namestring
Araris Biotech AG
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Araris Biotech AG is a Swiss biotechnology company founded in 2019 as a spin-off from the Paul Scherrer Institute (PSI) and ETH Zurich, headquartered in Au ZH, Switzerland. The company has developed a proprietary peptide linker technology platform for antibody-drug conjugates (ADCs), comprising AraLinQ® (a site-specific bioconjugation system targeting the Q295 residue on the IgG-Fc framework via transglutaminase) and Arastatin™ (a complementary linker-payload chemistry). Together, these platforms enable one-step payload attachment to off-the-shelf antibodies without re-engineering, producing homogeneous, stable, hydrophilic ADCs designed to improve therapeutic index over conventional conjugation methods.

Araris operates a B2B technology licensing and co-development model. Revenue is generated through upfront payments, research funding, milestone payments, and royalties tied to licensing its linker platforms to major pharmaceutical partners — including Taiho Pharmaceutical (now its parent), Chugai Pharmaceutical (up to USD 780 million in potential consideration), Johnson & Johnson, and Taiho Oncology. The company also maintains an internal pipeline: ARC-02 (CD79b-targeted, Phase 1 for non-Hodgkin lymphoma, first patient dosed June 2026), ARC-401 (Nectin-4, preclinical, solid tumors), and ARC-201 (NaPi2b, preclinical, solid tumors), with additional undisclosed targets in discovery. Following Taiho Pharmaceutical's full acquisition in March 2025, Araris operates as a wholly owned subsidiary building out Taiho's ADC pipeline while continuing to license its platform to third-party pharma.

Short descriptiontext

Araris Biotech AG is a Swiss ADC biotechnology company that develops proprietary AraLinQ® and Arastatin™ linker platforms for one-step, site-specific antibody-drug conjugate manufacturing, now operating as a wholly owned subsidiary of Taiho Pharmaceutical following its 2025 acquisition.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAu, Switzerland
HQ citystring
Au
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, ADC linker technology, site-specific bioconjugation, peptide linker chemistry, oncology drug development
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antibody-Drug Conjugates (ADC) Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Araris licenses its proprietary AraLinQ® technology platform to pharmaceutical partners. The Chugai agreement includes upfront payment plus potential milestone payments and royalties on commercial sales, with total potential consideration of up to USD 780 million.

ararisbiotech.com
2Research Collaborations
TypeProfessional Services
Description

Research agreements with pharmaceutical companies (Johnson & Johnson, Taiho Pharmaceutical) to develop next-generation ADCs using Araris' technology, generating revenue through research funding and potential future milestones.

ararisbiotech.com
3Internal Pipeline Development
TypeLicensing Royalties
Description

Development of proprietary ADC candidates (ARC-02, ARC-401, ARC-201) towards clinical development with goal of eventual commercialization or out-licensing.

ararisbiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Araris Biotech develops proprietary peptide linker technology for antibody-drug conjugate (ADC) development, marketed as the AraLinQ® platform with the Arastatin™ linker-payload system. The technology enables site-specific payload attachment to 'off-the-shelf' antibodies in a single enzymatic step without requiring antibody re-engineering, producing homogeneous, stable, and highly soluble ADCs. The company licenses this platform to pharmaceutical partners and develops an internal pipeline including ARC-02 (Phase 1), ARC-401, and ARC-201.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ARC-02 demonstrated superior anti-tumor efficacy compared to Roche's Polivy in preclinical studies targeting CD79b for non-Hodgkin lymphoma
+2 more records
Product overview1 text field

Araris Biotech is a spin-off from Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel proprietary ADC-linker technology platform. Their core offerings consist of the AraLinQ® ADC Technology Platform and Arastatin™ Linker-Payload Platform, which together enable site-specific payload attachment to 'off-the-shelf' antibodies in one step without antibody re-engineering. The technology produces homogeneous, stable, highly soluble, and high-quality ADC products in a cost-effective manner. The clinical pipeline includes ARC-02 (CD79b-targeted, Phase 1 for non-Hodgkin lymphoma), ARC-401 (Nectin-4 multi-payload ADC for solid tumors), and ARC-201 (NaPi2b multi-payload ADC for solid tumors), plus undisclosed targets.

Product and service5 records
1AraLinQ® ADC Technology Platform
CategoryADC Technology Platform
Description

Proprietary site-specific bioconjugation platform enabling payload attachment to a privileged attachment site on amino acid Q295 within the IgG-Fc framework using transglutaminase enzymes, allowing one-step conjugation to off-the-shelf antibodies for ADC development. Licensed to pharmaceutical partners for novel ADC therapeutics development.

2Arastatin™ Linker-Payload Platform
CategoryADC Linker-Payload Platform
Description

Proprietary linker-payload technology used in combination with AraLinQ® to generate next-generation antibody-drug conjugates with enhanced safety and antitumor effects, providing exceptional bloodstream stability and controlled payload release inside cancer cells.

3ARC-02
CategoryClinical-Stage ADC Drug Candidate
Description

CD79b-targeted antibody-drug conjugate for the treatment of non-Hodgkin lymphoma; first clinical candidate generated using Araris' AraLinQ® and Arastatin™ platforms. Demonstrated superior anti-tumor efficacy versus Roche's Polivy in preclinical studies. In Phase 1 clinical development as of June 2026.

4ARC-401
CategoryPreclinical ADC Drug Candidate
Description

Multi-payload antibody-drug conjugate targeting Nectin-4 for solid tumor indications; in discovery/preclinical development stage as a proprietary pipeline candidate.

5ARC-201
CategoryPreclinical ADC Drug Candidate
Description

Multi-payload antibody-drug conjugate targeting NaPi2b for solid tumor indications; in discovery/preclinical development stage as a proprietary pipeline candidate.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Taiho Oncology and Araris announced dosing of first patient in Phase 1 trial of ARC-02, a CD79b-targeted ADC for treatment of non-Hodgkin lymphoma. ARC-02 is the first clinical candidate generated using Araris' proprietary AraLinQ® ADC technology and Arastatin™ linker-payload platform.

2Chugai Pharmaceutical
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Chugai exercised its option under a Research Collaboration and Option to License Agreement to license Araris' proprietary AraLinQ® linker-payload platform for developing novel ADCs against one target selected by Chugai. Araris will receive upfront payment plus potential milestone payments and royalties on commercial sales, with total potential consideration of up to USD 780 million.

einpresswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-29
Description

Research agreement with Johnson & Johnson to develop next-generation antibody-drug conjugates using Araris' AraLinQ™ technology. Enhanced safety and antitumor effects demonstrated in preclinical studies, representing further validation of the technology.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

Taiho Pharmaceutical fully acquired Araris Biotech in March 2025 to strengthen its biologics and ADC research and development capabilities. Araris operates as a wholly owned subsidiary of Taiho Pharmaceutical, with the goal of establishing a strong Taiho ADC pipeline using the AraLinQ™ technology.

5Chugai Pharmaceutical (Initial Collaboration)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-08
Description

Research collaboration and option to license agreement with Chugai Pharmaceutical to generate novel ADCs using Araris' AraLinQ™ linker-conjugation platform with antibodies against targets provided by Chugai.

ararisbiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-08
Description

Research collaboration with Taiho Pharmaceutical for the development of next-generation ADCs using Araris' innovative linker-conjugation platform.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Pioneer in ADC technology acquired by AbbVie in 2024; developed the FDA-approved Elahere (mirvetuximab soravtansine) and operates a broad ADC pipeline. Comparable as a major ADC incumbent whose platform chemistry and clinical pipeline compete for similar oncology indications and pharma partnerships.

TypeDirect peer
Description

Clinical-stage ADC company developing Immunosynthen STING-agonist ADCs and Dolasynthen platform ADCs. Directly comparable as an ADC-platform biotech with proprietary conjugation chemistry and a clinical pipeline in oncology.

TypeDirect peer
Description

Clinical-stage ADC developer with commercial-stage loncastuximab tesirine (CD19-targeted) and a pipeline including camidanlumab tesirine. Direct competitor in the hematologic ADC space and one of the few ADC pure-plays with validated clinical-stage assets.

TypeBroad incumbent
Description

Major pharmaceutical company with the approved Polivy (polatuzumab vedotin) CD79b-targeted ADC, which Araris' ARC-02 directly benchmarks against. Comparable as the incumbent in CD79b hematologic oncology whose clinical results set the efficacy bar for Araris' lead candidate.

TypeBroad incumbent
Description

Leading ADC company acquired by Pfizer in 2023, with four approved ADCs (Adcetris, Padcev, Tukysa, Tivdak) and a deep clinical pipeline. Comparable as a broad ADC incumbent whose multiple approved products set the benchmark for ADC commercial success.

TypeEmerging player
Description

European ADC platform biotech (Munich) developing stable linker chemistries and a pipeline of clinical-stage ADCs. Comparable as a next-generation ADC platform with proprietary conjugation chemistry targeting solid tumors and hematologic malignancies.

TypeDirect peer
Description

German ADC company developing payloads and linkers based on amanitin toxin and licensing them to partners including Takeda and Eli Lilly. Comparable as an ADC-platform company with proprietary linker-payload technology and partnership-driven revenue model.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing Boltbody Immune-Stimulating Antibody Conjugates (ISACs). Comparable as an emerging antibody-conjugate platform company developing proprietary conjugation chemistry for cancer therapeutics.

TypeEmerging player
Description

Clinical-stage ADC and immuno-oncology company developing Microtubule-Inhibitor ADCs and antibody-drug conjugates against novel tumor antigens. Comparable as an ADC-focused biotech advancing a clinical pipeline of antibody-based cancer therapeutics.

TypeBroad incumbent
Description

Japanese pharmaceutical company with industry-leading DXd ADC platform and FDA-approved Enhertu and Datroway in partnership with AstraZeneca. Comparable as the dominant ADC platform incumbent whose linker-payload chemistry (DXd) competes with Araris' AraLinQ/Arastatin platform for pharma partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Araris Biotech

Antibody-Drug Conjugates (ADC) Biopharmaceuticalsararisbiotech.com

Araris Biotech AG is a Swiss ADC biotechnology company that develops proprietary AraLinQ® and Arastatin™ linker platforms for one-step, site-specific antibody-drug conjugate manufacturing, now operating as a wholly owned subsidiary of Taiho Pharmaceutical following its 2025 acquisition.

What Araris Biotech does

Araris Biotech AG is a Swiss biotechnology company founded in 2019 as a spin-off from the Paul Scherrer Institute (PSI) and ETH Zurich, headquartered in Au ZH, Switzerland. The company has developed a proprietary peptide linker technology platform for antibody-drug conjugates (ADCs), comprising AraLinQ® (a site-specific bioconjugation system targeting the Q295 residue on the IgG-Fc framework via transglutaminase) and Arastatin™ (a complementary linker-payload chemistry). Together, these platforms enable one-step payload attachment to off-the-shelf antibodies without re-engineering, producing homogeneous, stable, hydrophilic ADCs designed to improve therapeutic index over conventional conjugation methods.

Araris operates a B2B technology licensing and co-development model. Revenue is generated through upfront payments, research funding, milestone payments, and royalties tied to licensing its linker platforms to major pharmaceutical partners — including Taiho Pharmaceutical (now its parent), Chugai Pharmaceutical (up to USD 780 million in potential consideration), Johnson & Johnson, and Taiho Oncology. The company also maintains an internal pipeline: ARC-02 (CD79b-targeted, Phase 1 for non-Hodgkin lymphoma, first patient dosed June 2026), ARC-401 (Nectin-4, preclinical, solid tumors), and ARC-201 (NaPi2b, preclinical, solid tumors), with additional undisclosed targets in discovery. Following Taiho Pharmaceutical's full acquisition in March 2025, Araris operates as a wholly owned subsidiary building out Taiho's ADC pipeline while continuing to license its platform to third-party pharma.

Araris Biotech firmographics

Firmographics
Name
Araris Biotech
Legal name
Araris Biotech AG
Website
https://ararisbiotech.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Araris Biotech AG is a Swiss ADC biotechnology company that develops proprietary AraLinQ® and Arastatin™ linker platforms for one-step, site-specific antibody-drug conjugate manufacturing, now operating as a wholly owned subsidiary of Taiho Pharmaceutical following its 2025 acquisition.
Ownership category
akta.pro rank

Araris Biotech industry classification

Industry
Product category
Antibody-Drug Conjugates (ADC) Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody-drug conjugates
  • ADC linker technology
  • Site-specific bioconjugation
  • Peptide linker chemistry
  • Oncology drug development

Where Araris Biotech is headquartered

Location

Headquarters

HQ city
Au
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Araris Biotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Milestone Payments: Araris licenses its proprietary AraLinQ® technology platform to pharmaceutical partners. The Chugai agreement includes upfront payment plus potential milestone payments and royalties on commercial sales, with total potential consideration of up to USD 780 million.
  2. Research Collaborations: Research agreements with pharmaceutical companies (Johnson & Johnson, Taiho Pharmaceutical) to develop next-generation ADCs using Araris' technology, generating revenue through research funding and potential future milestones.
  3. Internal Pipeline Development: Development of proprietary ADC candidates (ARC-02, ARC-401, ARC-201) towards clinical development with goal of eventual commercialization or out-licensing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Araris Biotech product offering

Product offering

Core offering

Araris Biotech develops proprietary peptide linker technology for antibody-drug conjugate (ADC) development, marketed as the AraLinQ® platform with the Arastatin™ linker-payload system. The technology enables site-specific payload attachment to 'off-the-shelf' antibodies in a single enzymatic step without requiring antibody re-engineering, producing homogeneous, stable, and highly soluble ADCs. The company licenses this platform to pharmaceutical partners and develops an internal pipeline including ARC-02 (Phase 1), ARC-401, and ARC-201.

Product overview

Araris Biotech is a spin-off from Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel proprietary ADC-linker technology platform. Their core offerings consist of the AraLinQ® ADC Technology Platform and Arastatin™ Linker-Payload Platform, which together enable site-specific payload attachment to 'off-the-shelf' antibodies in one step without antibody re-engineering. The technology produces homogeneous, stable, highly soluble, and high-quality ADC products in a cost-effective manner. The clinical pipeline includes ARC-02 (CD79b-targeted, Phase 1 for non-Hodgkin lymphoma), ARC-401 (Nectin-4 multi-payload ADC for solid tumors), and ARC-201 (NaPi2b multi-payload ADC for solid tumors), plus undisclosed targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • AraLinQ® ADC Technology Platform Proprietary site-specific bioconjugation platform enabling payload attachment to a privileged attachment site on amino acid Q295 within the IgG-Fc framework using transglutaminase enzymes, allowing one-step conjugation to off-the-shelf antibodies for ADC development. Licensed to pharmaceutical partners for novel ADC therapeutics development.
  • Arastatin™ Linker-Payload Platform Proprietary linker-payload technology used in combination with AraLinQ® to generate next-generation antibody-drug conjugates with enhanced safety and antitumor effects, providing exceptional bloodstream stability and controlled payload release inside cancer cells.
  • ARC-02 CD79b-targeted antibody-drug conjugate for the treatment of non-Hodgkin lymphoma; first clinical candidate generated using Araris' AraLinQ® and Arastatin™ platforms. Demonstrated superior anti-tumor efficacy versus Roche's Polivy in preclinical studies. In Phase 1 clinical development as of June 2026.
  • ARC-401 Multi-payload antibody-drug conjugate targeting Nectin-4 for solid tumor indications; in discovery/preclinical development stage as a proprietary pipeline candidate.
  • ARC-201 Multi-payload antibody-drug conjugate targeting NaPi2b for solid tumor indications; in discovery/preclinical development stage as a proprietary pipeline candidate.

Quantifiable outcome

  • ARC-02 demonstrated superior anti-tumor efficacy compared to Roche's Polivy in preclinical studies targeting CD79b for non-Hodgkin lymphoma
  • +2 more outcomes

Companies that use Araris Biotech

Customer profile

Segments3 records

Ideal customer profiles2 records

Araris Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Araris Biotech partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship and core.

  • Taiho OncologyflagshipStrategic or Co-development Partner · 23 June 2026Taiho Oncology and Araris announced dosing of first patient in Phase 1 trial of ARC-02, a CD79b-targeted ADC for treatment of non-Hodgkin lymphoma. ARC-02 is the first clinical candidate generated using Araris' proprietary AraLinQ® ADC technology and Arastatin™ linker-payload platform.
  • Chugai PharmaceuticalcoreStrategic or Co-development Partner · 10 February 2026Chugai exercised its option under a Research Collaboration and Option to License Agreement to license Araris' proprietary AraLinQ® linker-payload platform for developing novel ADCs against one target selected by Chugai. Araris will receive upfront payment plus potential milestone payments and royalties on commercial sales, with total potential consideration of up to USD 780 million.
  • Johnson & JohnsoncoreStrategic or Co-development Partner · 29 April 2025Research agreement with Johnson & Johnson to develop next-generation antibody-drug conjugates using Araris' AraLinQ™ technology. Enhanced safety and antitumor effects demonstrated in preclinical studies, representing further validation of the technology.
  • Taiho PharmaceuticalflagshipStrategic or Co-development Partner · 1 March 2025Taiho Pharmaceutical fully acquired Araris Biotech in March 2025 to strengthen its biologics and ADC research and development capabilities. Araris operates as a wholly owned subsidiary of Taiho Pharmaceutical, with the goal of establishing a strong Taiho ADC pipeline using the AraLinQ™ technology.
  • Chugai Pharmaceutical (Initial Collaboration)coreStrategic or Co-development Partner · 8 January 2025Research collaboration and option to license agreement with Chugai Pharmaceutical to generate novel ADCs using Araris' AraLinQ™ linker-conjugation platform with antibodies against targets provided by Chugai.
  • Taiho Pharmaceutical (Research Collaboration)coreStrategic or Co-development Partner · 8 November 2023Research collaboration with Taiho Pharmaceutical for the development of next-generation ADCs using Araris' innovative linker-conjugation platform.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Araris Biotech competitors and assessment

Company assessment

Broad incumbents

  • ImmunoGen: Pioneer in ADC technology acquired by AbbVie in 2024; developed the FDA-approved Elahere (mirvetuximab soravtansine) and operates a broad ADC pipeline. Comparable as a major ADC incumbent whose platform chemistry and clinical pipeline compete for similar oncology indications and pharma partnerships.
  • Roche: Major pharmaceutical company with the approved Polivy (polatuzumab vedotin) CD79b-targeted ADC, which Araris' ARC-02 directly benchmarks against. Comparable as the incumbent in CD79b hematologic oncology whose clinical results set the efficacy bar for Araris' lead candidate.
  • Seagen: Leading ADC company acquired by Pfizer in 2023, with four approved ADCs (Adcetris, Padcev, Tukysa, Tivdak) and a deep clinical pipeline. Comparable as a broad ADC incumbent whose multiple approved products set the benchmark for ADC commercial success.
  • Daiichi Sankyo: Japanese pharmaceutical company with industry-leading DXd ADC platform and FDA-approved Enhertu and Datroway in partnership with AstraZeneca. Comparable as the dominant ADC platform incumbent whose linker-payload chemistry (DXd) competes with Araris' AraLinQ/Arastatin platform for pharma partnerships.

Direct peers

  • Mersana Therapeutics: Clinical-stage ADC company developing Immunosynthen STING-agonist ADCs and Dolasynthen platform ADCs. Directly comparable as an ADC-platform biotech with proprietary conjugation chemistry and a clinical pipeline in oncology.
  • ADC Therapeutics: Clinical-stage ADC developer with commercial-stage loncastuximab tesirine (CD19-targeted) and a pipeline including camidanlumab tesirine. Direct competitor in the hematologic ADC space and one of the few ADC pure-plays with validated clinical-stage assets.
  • Heidelberg Pharma: German ADC company developing payloads and linkers based on amanitin toxin and licensing them to partners including Takeda and Eli Lilly. Comparable as an ADC-platform company with proprietary linker-payload technology and partnership-driven revenue model.

Emerging players

  • Tubulis: European ADC platform biotech (Munich) developing stable linker chemistries and a pipeline of clinical-stage ADCs. Comparable as a next-generation ADC platform with proprietary conjugation chemistry targeting solid tumors and hematologic malignancies.
  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing Boltbody Immune-Stimulating Antibody Conjugates (ISACs). Comparable as an emerging antibody-conjugate platform company developing proprietary conjugation chemistry for cancer therapeutics.
  • Pyxis Oncology: Clinical-stage ADC and immuno-oncology company developing Microtubule-Inhibitor ADCs and antibody-drug conjugates against novel tumor antigens. Comparable as an ADC-focused biotech advancing a clinical pipeline of antibody-based cancer therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Araris Biotech social profiles

Digital presence

Araris Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Araris Biotech leadership team

Management profile

Number of profiles

Profiles7 records

Araris Biotech funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Araris Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Araris Biotech

What does Araris Biotech do?

Araris Biotech develops proprietary peptide linker technology for antibody-drug conjugate (ADC) development, marketed as the AraLinQ® platform with the Arastatin™ linker-payload system. The technology enables site-specific payload attachment to 'off-the-shelf' antibodies in a single enzymatic step without requiring antibody re-engineering, producing homogeneous, stable, and highly soluble ADCs. The company licenses this platform to pharmaceutical partners and develops an internal pipeline including ARC-02 (Phase 1), ARC-401, and ARC-201.

Is Araris Biotech a public or private company?

Araris Biotech is a private company. It is classified as corporate owned and is currently operating.

When was Araris Biotech founded?

Araris Biotech was founded in 2019. It employs 11 to 50 people.

Where is Araris Biotech based?

Araris Biotech is headquartered in Au, Switzerland, in the Europe region.

How does Araris Biotech make money?

Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are research Collaborations and internal Pipeline Development.

Who are Araris Biotech's main competitors?

Broad incumbents on record are ImmunoGen, Roche, Seagen and Daiichi Sankyo. Direct peers are Mersana Therapeutics, ADC Therapeutics and Heidelberg Pharma. Emerging players are Tubulis, Bolt Biotherapeutics and Pyxis Oncology.

Does Araris Biotech have an API?

No public API is recorded for Araris Biotech.

What industry is Araris Biotech in?

Araris Biotech's product category is Antibody-Drug Conjugates (ADC) Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyThe Strüngmann legacy, passed onThe Strüngmann family office launched the Strüngmann Award to recognize European biotech entrepreneurs, with a €100,000 prize. The 2026 winner is Jonathan Talbot of Mosanna and Melodia Therapeutics. The award will expand beyond Germany, Austria, and Switzerland to include more of Europe.European Biotechnology8 European VC firms to watch in 2026Eight European VC firms are profiled for 2026, including Jeito Capital, Sofinnova Partners, and Medicxi, with fund sizes and recent exits. The list highlights firms that closed new biotech funds in the past year, such as Jeito II at $1.2 billion and Medicxi V at €500 million. The firms are positioned as shaping the continent's investment landscape amid tighter capital.Business Wire BlogAraris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin LymphomaAraris Biotech AG and Taiho Oncology announced that the first patient has been dosed in a Phase 1 clinical trial of ARC-02, a CD79b-targeted antibody-drug conjugate for the treatment of non-Hodgkin lymphoma. ARC-02 is the first clinical candidate generated using Araris' proprietary AraLinQ® ADC technology and Arastatin™ linker-payload platform, which enables site-specific payload attachment to antibodies for targeted cancer therapy. The milestone marks Taiho Oncology's expansion into the clinical development of ADCs for oncology and represents the first human experience with the Araris ADC platform.BioSpaceTaiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical DevelopmentTaiho Oncology, Taiho Pharmaceutical, and Araris Biotech announced the FDA completed its IND review for ARC-02, an antibody-drug conjugate for non-Hodgkin lymphoma, enabling a Phase 1 dose-escalation trial. The trial is the first clinical trial of a product using Araris' AraLinQ™ ADC technology, marking Taiho's expansion into ADC development.Business Wire BlogTaiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical DevelopmentThe FDA completed its IND review for ARC-02, enabling Taiho Oncology to initiate a Phase 1 dose-escalation trial of this CD79b-targeting antibody-drug conjugate for non-Hodgkin lymphoma patients. The trial marks the first clinical application of Araris Biotech's proprietary AraLinQ™ ADC technology and represents Taiho Pharmaceutical's expansion into ADC-based oncology therapies. Taiho Pharmaceutical acquired Araris Biotech in March 2025 to strengthen its biologics and ADC research and development capabilities.EIN PresswireChugai and Araris Biotech AG Enter License Agreement for Araris' Linker-Payload ADC Technology AraLinQ®Chugai Pharmaceutical Co., Ltd. has exercised its option under a Research Collaboration and Option to License Agreement with Araris Biotech AG to license Araris' proprietary AraLinQ® linker-payload platform for developing novel antibody-drug conjugates against one target selected by Chugai. With the option exercise, Araris will receive an immediate upfront payment plus potential milestone payments and royalties on commercial sales, with total potential consideration of up to USD 780 million. The collaboration aims to combine Araris' AraLinQ® technology with Chugai's antibody engineering capabilities to create innovative cancer therapeutics with enhanced efficacy and safety.FierceBiotechJPM26: Chugai chases new science and name recognition from US biopharma industryChugai Pharmaceutical's leadership is attending the J.P. Morgan Annual Healthcare Conference in San Francisco to build name recognition in the U.S. biopharma industry and seek new external partnerships amid a strategic shift away from its traditional internal R&D model. The Japanese pharma company, which invented Roche's hemophilia drug Hemlibra and the GLP-1 weight loss candidate orforglipron licensed to Eli Lilly, has recently signed collaborations with Rani Therapeutics for oral antibody delivery and Araris Biotech for ADC linker technology worth up to $780 million. Chugai is also advancing its partnership with Nobel laureate Shimon Sakaguchi on a regulatory T-cell targeting antibody in Phase 1 trials, while managing its $200 million Boston-based venture fund focused on U.S. and European biotech investments.Digital JournalSwiss life sciences start-up scene will ‘continue to flourish’ in 2026The 2025 European Spinouts Report highlights Switzerland's life sciences start-up ecosystem as a global leader, particularly when adjusted for population size and STEM graduates. A standout transaction was Taiho Pharmaceutical's USD 1.1 billion acquisition of Araris Biotech in March, validating Switzerland's strength in academic spinouts. Venture capital activity remained robust, with Biopôle campus raising 756 million CHF in 2025, and accelerators like BaseLaunch continuing to support early-stage companies.GlobeNewswireStrüngmann Award Honors Araris Biotech Founding Team asThe Strüngmann Award jury selected Araris Biotech founders Dragan Grabulovski, Philipp Spycher, and Isabella Attinger-Toller, awarding them a EUR 100,000 cash prize. The team developed a novel antibody-drug conjugate technology and was acquired by Taiho Pharmaceuticals for up to USD $1.14 billion in March 2025.GlobeNewswireStrüngmann Award Honors Araris Biotech Founding Team asThe Strüngmann Award jury selected Araris Biotech founders Dragan Grabulovski, Philipp Spycher, and Isabella Attinger-Toller as winners, awarding them a EUR 100,000 cash prize. The team developed a novel antibody-drug conjugate technology and was acquired by Taiho Pharmaceuticals for up to USD $1.14 billion in March 2025.